A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes

Ovarian Cancer Association Consortium, International Endometriosis Genetics Consortium

Research output: Contribution to journalArticle (Academic Journal)peer-review

30 Citations (Scopus)
211 Downloads (Pure)
Original languageEnglish
Article number100542
Number of pages21
JournalCell Reports Medicine
Volume3
Issue number3
DOIs
Publication statusPublished - 15 Mar 2022

Bibliographical note

Funding Information:
This work was supported by the National Health and Medical Research Council of Australia ( GNT1026033 , GNT1105321 , GNT1147846 , Investigator Grant 1177194 to G.W.M. and Medical Research Future Fund Research grant MRF1199785 to S.M.) and National Institutes of Health ( R01CA193910 , R01CA204954 , R01CA211707 , R01CA251555 ). S.P.K. is supported by a United Kingdom Research and Innovation Future Leaders Fellowship (MR/T043202/1). K.L. is supported by a Liz Tilberis Early Career Award (599175) and a Program Project Development (373356) from the Ovarian Cancer Research Alliance , plus a Research Scholar’s Grant from the American Cancer Society ( 134005 ). For funding details of the endometriosis meta-analysis, please see Sapkota et al. 17 For funding details of the ovarian cancer meta-analysis, please see Phelan et al. 18

Funding Information:
We would like to thank the research participants and employees of 23andMe for making this work possible. We would like to acknowledge the International Endometriosis Genetics Consortium and Ovarian Cancer Association Consortium for their contributions generating the GWAS datasets and data access. We are grateful to the thousands of patients who donated the specimens that enable this research to happen. For specific acknowledgments for the endometriosis meta-analysis, please see Sapkota et al.17 For specific acknowledgments for the ovarian cancer meta-analysis, please see Phelan et al.18 The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 06/26/20. This work was supported by the National Health and Medical Research Council of Australia (GNT1026033, GNT1105321, GNT1147846, Investigator Grant 1177194 to G.W.M. and Medical Research Future Fund Research grant MRF1199785 to S.M.) and National Institutes of Health (R01CA193910, R01CA204954, R01CA211707, R01CA251555). S.P.K. is supported by a United Kingdom Research and Innovation Future Leaders Fellowship (MR/T043202/1). K.L. is supported by a Liz Tilberis Early Career Award (599175) and a Program Project Development (373356) from the Ovarian Cancer Research Alliance, plus a Research Scholar's Grant from the American Cancer Society (134005). For funding details of the endometriosis meta-analysis, please see Sapkota et al.17 For funding details of the ovarian cancer meta-analysis, please see Phelan et al.18, S.M. S.P.K. K.L. G.W.M. and P.P. designed the study with input from the other authors. Data analyzed in this study were generated by the Ovarian Cancer Association Consortium and International Endometriosis Genetics Consortium. S.M. and S.P.K. ran additional quality control and filtering of GWAS datasets. J.-H.S. M.L.F. S.A.G. M.T.S. R.L. C.W. I.C. B.Y.K. P.A.W.R. and B.J.R. contributed to specimen collection and data generation. Data analysis was performed by S.M. S.P.K. R.I.C. and P.F.K. which was interpreted by all authors. S.M. S.P.K. and K.L. drafted the report with input from all other authors. The final manuscript has been critically revised and approved by all authors. M.L.F. reports other support from Nuscan Diagnostics outside the scope of the submitted work. C.W. reports research funding support from Merck, is a member of the Immunogen advisory board (1/2022), and has been a member of the Genentech advisory board (8/2020). The remaining authors declare no competing interests.

Funding Information:
We would like to thank the research participants and employees of 23andMe for making this work possible. We would like to acknowledge the International Endometriosis Genetics Consortium and Ovarian Cancer Association Consortium for their contributions generating the GWAS datasets and data access. We are grateful to the thousands of patients who donated the specimens that enable this research to happen. For specific acknowledgments for the endometriosis meta-analysis, please see Sapkota et al. 17 For specific acknowledgments for the ovarian cancer meta-analysis, please see Phelan et al. 18 The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 06/26/20.

Funding Information:
M.L.F. reports other support from Nuscan Diagnostics outside the scope of the submitted work. C.W. reports research funding support from Merck, is a member of the Immunogen advisory board (1/2022), and has been a member of the Genentech advisory board (8/2020). The remaining authors declare no competing interests.

Publisher Copyright:
© 2022 The Authors

Keywords

  • endometriosis
  • epithelial ovarian cancer
  • genetic correlation
  • Mendelian randomization
  • meta-analysis
  • genetic risk
  • histotype
  • genetic association

Cite this